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Background. The prospective identiﬁcation of patients at high risk for hospital-acquired/ventilator-associated bacterial
pneumonia may improve clinical trial feasibility and foster antibacterial development. In a prior study conducted in the United
States, clinical criteria were used to prospectively identify these patients; however, these criteria have not been applied in a
European population.
Methods. Adults considered high risk for pneumonia (treatment with ventilation or high levels of supplemental oxygen) in the
intensive care units of 7 European hospitals were prospectively enrolled from June 12 to December 27, 2017. We estimated the
proportion of high-risk patients developing pneumonia according to US Food and Drug Administration guidance and a subset
potentially eligible for antibacterial trial enrollment. We compared patient characteristics, treatment exposures, and pneumonia
incidence in a European cohort and a previously described US cohort.
Results. Of 888 high-risk patients, 211/888 (24%) were treated for possible pneumonia, and 150/888 (17%) met the Food and
Drug Administration deﬁnition for hospital-acquired/ventilator-associated bacterial pneumonia. A higher proportion of European
patients treated for possible pneumonia met the pneumonia deﬁnition (150/211 [71%] vs 537/1464 [37%]; P , .001). Among
patients developing pneumonia, a higher proportion of European patients met antibacterial trial eligibility criteria (124/150
[83%] vs 371/537 [69%]; P , .001).
Conclusions. Clinical criteria prospectively identiﬁed high-risk patients with high rates of pneumonia in the European cohort.
Despite higher rates of established risk factors and incident pneumonia, European patients were signiﬁcantly less likely to receive
antibiotics for possible pneumonia than US patients. Different treatment practices may contribute to lower rates of antibacterial trial
enrollment in the United States.
Keywords. antibacterial agent; bacterial pneumonia; health care–associated pneumonia; intensive care unit; mechanical
ventilator.
New antibacterial agents with proven efﬁcacy in the treatment of
hospital-acquired bacterial pneumonia (HABP) and ventilatorassociated bacterial pneumonia (VABP) are needed to combat
increasing rates of infection caused by antimicrobial-resistant
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pathogens [1, 2]. Additionally, unanticipated limitations of currently available antibacterial drugs initially approved for other
clinical indications underscore the need to rigorously evaluate
new antibacterial agents in well-designed HABP/VABP clinical
trials [3–6]. Despite the urgent need, few registrational trials
evaluating new antibacterial agents for HABP/VABP treatment
have been completed over the past decade [7–12]. Multiple contributors to the economic inefﬁciencies of HABP/VABP antibacterial development have been identiﬁed [13]. Declining rates of
nosocomial pneumonia and high rates of screening failure, partially due to prolonged exposure to potentially effective prior antibacterial drug therapy, are commonly implicated drivers of
excessive clinical trial cost [14, 15].
We recently reported ﬁndings from a large cohort of critically ill patients hospitalized in 28 US centers who were prospectively identiﬁed as high risk for developing HABP/VABP [16].
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PROPHETIC EU: Prospective Identiﬁcation of Pneumonia
in Hospitalized Patients in the Intensive Care Unit in
European and United States Cohorts

METHODS
Study Design

This multicenter, prospective, observational cohort study was
conducted in the ICUs of 7 European hospitals before the
COVID-19 pandemic. Enrolling sites comprised a diverse group
of community and academic medical centers with a median size
(range) of 850 (600–1300) inpatient beds located in Belgium (1),
Spain (2), and the Netherlands (4). The study protocol was identical to that employed in the CTTI US cohort study and has been
previously described [16]. Brieﬂy, eligible adult patients admitted to the ICUs of participating centers were screened for the
presence of predeﬁned risk factors for HABP/VABP development. Patients meeting the study-deﬁned high-risk criteria
were enrolled and prospectively followed through their ICU
stay for exposure to antibacterial drugs administered for treatment of possible nosocomial pneumonia.
Patient Consent

The study protocol was approved, and a waiver of informed
consent was granted by an independent review board
(Copernicus Group, CTTI_001, DCR2-15-710) or, when required, the institutional review board of participating US institutions, and by ethics committees from each country in Europe.
Deﬁnitions

The high-risk population was deﬁned as patients receiving high
levels of respiratory support (invasive mechanical ventilation,
noninvasive ventilation, or treatment with at least 50% fraction
2 • OFID • Bergin et al

of inspired supplemental oxygen delivered by partial or nonrebreather mask, aerosol mask, or high-ﬂow, high-humidity nasal
cannula for a minimum of 12 hours within any 24-hour period
in the 7 days before enrollment) (Supplementary Table 1).
Additionally, high-risk patients lacked criteria to fulﬁll the
study HABP/VABP deﬁnition upon enrollment. The treated
population was deﬁned as the subset of high-risk patients
with antibacterials for treatment of possible pneumonia ordered in the electronic health record before ICU discharge.
Antibacterial drug indications were assigned by review of clinician documentation and indications associated with antibacterial drug orders. Antibacterial drugs administered for the
treatment of clinically suspected pneumonia or suspected
pneumonia-induced sepsis were included. The HABP/VABP
population was deﬁned as the subset of the treated population
fulﬁlling the study HABP/VABP deﬁnition. The HABP/VABP
study deﬁnition required the presence of at least 1 criterion
from the radiographic criteria, systemic inﬂammation, timing
of symptom onset, and respiratory signs and symptoms domains (Supplementary Table 2). The study HABP/VABP deﬁnition was identical to the US PROPHETIC study deﬁnition
previously developed for consistency with treatment guidelines
and the US Food and Drug Administration’s (FDA’s) draft
guidance to industry for HABP/VABP drug development [16,
18, 19]. Because this study was designed to estimate the number
of high-risk patients who might be eligible for enrollment in
antibacterial trials submitted to the US FDA in support of approval of new HABP/VABP treatments, European regulatory
agency recommendations were not incorporated into a modiﬁed study HABP/VABP deﬁnition.
Outcomes

The primary outcome was the proportion of prospectively
identiﬁed high-risk patients meeting the study HABP/VABP
deﬁnition. The key secondary outcome was the proportion of
HABP/VABP patients meeting FDA-recommended eligibility
criteria for enrollment in an HABP/VABP antibacterial trial.
Statistical Analyses

All statistical analyses were performed in the prespeciﬁed study
populations. Patient characteristics and treatment exposures
were summarized as frequencies and percentages for categorical variables and as medians with 25th and 75th percentiles for
continuous variables. The Wilcoxon rank-sum test was used to
compare the continuous variables of interest between the
European and US populations. The Pearson chi-square test
or Fisher exact test was used for the categorical variables.
Utilizing the same methodology employed in the US cohort,
a multivariable logistic regression model was developed to evaluate and compare patient characteristics and treatment exposures associated with an increased risk of HABP/VABP
development during the ICU course [16]. Brieﬂy, only variables
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Of the 4613 patients enrolled, 32% received antibacterials for
treatment of possible nosocomial pneumonia and 12% developed HABP or VABP during their intensive care unit (ICU)
course. Whether these ﬁndings are applicable in critically ill
populations outside the United States, where different epidemiology or treatment practices exist, is unknown. In contemporary antibacterial drug registrational trials, the vast majority
of patients are enrolled outside the United States [7, 17]. The
underlying drivers of the higher HABP/VABP clinical trial enrollment rates observed in Europe, vs the United States, are not
well characterized.
The Clinical Trials Transformation Initiative (CTTI) HABP/
VABP studies team designed this multicenter cohort study of
prospectively identiﬁed patients in Europe, which (1) deﬁned
the incidence of HABP/VABP in a cohort of critically ill patients fulﬁlling previously described high-risk clinical criteria;
(2) estimated the proportion of HABP/VABP patients eligible
for enrollment in nosocomial pneumonia antibacterial drug trials; and (3) compared patient characteristics and treatment exposures in contemporary European and US cohorts to better
understand observed differences in HABP/VABP incidence
and clinical trial eligibility.

≥

documented upon enrollment into the high-risk population
were evaluated in the multivariable model. Final predictors
identiﬁed using clinical guidance and a backward variable selection process at the .1 level of signiﬁcance for model inclusion
were conﬁrmed independently using a forward variable selection
process. The discriminatory capacity of the multivariable model
was assessed using the c-statistic. Goodness of ﬁt for the multivariable model was assessed with the Hosmer-Lemeshow test.
SAS, version 9.4, was used for all analyses.

RESULTS

From June 12 to December 27, 2017, a total of 1005 ICU patients were enrolled: 888 (88%) met the prespeciﬁed study criteria and were included in the high-risk population (Figure 1).
Among 1005 enrolled patients, 89 (9%) were excluded from the
high-risk population because HABP/VABP was present at the
time of study enrollment. Of 888 high-risk patients, 150
(17%) met the study HABP/VABP deﬁnition. The median hospital length of stay at the time of HABP/VABP development
(range) was 8 (5–13) days (Figure 2). Among 142/150 (95%) patients meeting HABP/VABP criteria and exposed to invasive
mechanical ventilation, 131 (92%) VABP and 11 (8%) ventilated HABP cases were identiﬁed. In the subset of high-risk patients developing VABP, the median duration of invasive

mechanical ventilation at the time of VABP diagnosis (range)
was 10 (6–15) days.
Demographics, medical comorbidities, and treatment exposures of European high-risk patients were compared with those
observed in the contemporary US study cohort (Table 1).
High-risk patients in the European cohort were older (63
[51.5–73] vs 61 [50–70] years; P = .003), had a lower body
mass index (26.2 [23.5–29.9] vs 28.9 [24.1–35.0] kg/m2; P ,
.001), and were more commonly admitted to a mixed medical–surgical ICU (85% vs 4%; P , .001). No signiﬁcant differences were observed in the rates or duration of exposure to
invasive or noninvasive ventilation. Excluding pharmacologic
gastric acid suppression and documented aspiration risk, patient characteristics and treatment exposures associated with
a higher risk of HABP/VABP development in the US cohort
(ICU admission for trauma or cerebrovascular accident, receipt
of enteral nutrition, and exposure to systemic antibacterials
within the preceding 90 days) were observed in higher proportions of high-risk patients in the European cohort. Selective
oropharyngeal decontamination (SOD) or selective decontamination of the digestive tract (SDD) was administered to 356/422
(84%) high-risk patients enrolled in the Netherlands and 4/466
(1%) high-risk patients enrolled in Spain or Belgium. None of
the 28 sites enrolling in the United States reported use of SOD
or SDD on a site questionnaire.
Pneumonia in Two High-risk ICU Populations • OFID • 3
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Figure 1. Screening, eligibility, and enrollment of ICU patients at risk for nosocomial pneumonia. Abbreviations: HABP/VABP, hospital-acquired bacterial pneumonia/
ventilator-associated bacterial pneumonia; ICU, intensive care unit.

In the European high-risk population, 150 of 888 (17%) patients developed HABP/VABP, a signiﬁcantly higher proportion than that observed in the US high-risk cohort (537/4613
[12%]; P , .001) (Figure 3A). Among high-risk patients in
the European cohort, 211/888 (24%) received antibiotics for
treatment of possible pneumonia, a signiﬁcantly lower proportion than the 1464/4613 (32%) treated patients observed in the
US high-risk cohort (P , .001). Whereas 150/211 (71%) highrisk patients treated for pneumonia in the European cohort
met the study HABP/VABP criteria, 537/1464 (37%) treated
patients in the US cohort fulﬁlled the HABP/VABP criteria
(P , .001). In both cohorts, the most common reason that
high-risk patients treated for pneumonia did not meet the
study HABP/VABP deﬁnition was the lack of radiographic criteria (64% in both Europe and the United States). A signiﬁcantly higher proportion of patients treated for possible
pneumonia in the US cohort lacked diagnostic criteria across
all required HABP/VABP diagnostic domains (Figure 3B).
4 • OFID • Bergin et al

Among 150 HABP/VABP patients in the European cohort,
124 (83%), or 14% of the enrolled high-risk population (n =
888), had been exposed to ,24 hours of potentially effective
antibacterial therapy at the time of HABP/VABP diagnosis, fulﬁlling the FDA-recommended eligibility criteria for enrollment
in HABP/VABP antibacterial trials (Figure 4). In the US cohort,
371/537 (69%) HABP/VABP patients, or 8% of the entire highrisk population, met the recommended HABP/VABP trial eligibility criteria (P , .001). Of the 124 HABP/VABP patients
meeting recommended eligibility criteria in Europe, 45 (36%)
had at least 1 additional exclusion criterion commonly employed in HABP/VABP clinical trials—a signiﬁcantly lower
proportion than the 212/371 (57%) HABP/VABP patients otherwise meeting recommended eligibility criteria in the US cohort (P , .001).
The multivariable logistic regression model included all 888
high-risk patients from the European cohort. Consistent with
the US model, ICU admission diagnoses of trauma or
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Figure 2. Cumulative incidence of HABP/VABP in Europe and the United States. Abbreviation: HABP/VABP, hospital-acquired bacterial pneumonia/ventilator-associated
bacterial pneumonia.

Table 1. Characteristics of European and United States Populations at High Risk for Pneumonia
Characteristic

Europe High-Risk Patients (n = 888)

United States High-Risk Patients (n = 4613)

P Value

Demographicsa
Age, median (IQR), y

63.0 (51.5–73.0)

61.0 (50.0–70.0)

Female sex, No. (%)

302 (34.0)

2058 (44.6)

Body mass index, median (IQR), kg/m2

.003
,.001

26.2 (23.5–29.9)

28.9 (24.1–35.0)

,.001

Hospital length of stay, median (IQR), d

2.0 (2.0–5.0)

4.0 (3.0–8.0)

,.001

ICU length of stay, median (IQR), d

2.0 (1.0–2.0)

3.0 (2.0–5.0)

,.001

Invasive mechanical ventilation

735 (82.8)

3908 (84.7)

.143

Noninvasive mechanical ventilation

144 (16.2)

751 (16.3)

.962

Enteral nutritionc

681 (76.7)

3035 (65.8)

,.001

Vasopressor/inotropic therapy

690 (77.7)

2211 (47.9)

,.001

Biologic agents, current hospitalization

12 (1.4)

169 (3.7)

,.001

Corticosteroids, current hospitalization

142 (16.0)

589 (12.8)

.010

PPI/H-2 blocker, current hospitalizationc

631 (71.1)

3475 (75.3)

.007

Blood product transfusion, prior 7 d

361 (40.7)

1062 (23.0)

,.001

Systemic antibacterials, prior 90 dc

579 (65.2)

2832 (61.4)

.032

Mechanical circulatory support

51 (5.7)

220 (4.8)

Massive volume resuscitation

149 (16.8)

532 (11.5)

,.001
,.001

.219

Active medical problems, No. (%)b,d
Acute respiratory distress syndrome
Acute kidney injury
Chronic kidney disease

55 (6.2)

686 (14.9)

174 (19.6)

1078 (23.4)

.014

59 (6.6)

541 (11.7)

,.001

6 (0.7)

270 (5.9)

,.001

Aspiration riskc

49 (5.5)

605 (13.1)

,.001

Autoimmune disorder

32 (3.6)

194 (4.2)

Chemotherapy, prior 30 d

11 (1.2)

139 (3.0)

190 (21.4)

1304 (28.3)

,.001

Immunocompromised

78 (8.8)

545 (11.8)

.009

Chronic respiratory failure

37 (4.2)

129 (2.8)

.029

Congestive heart failure, NYHA class IV

45 (5.3)

141 (3.3)

Cirrhosis or gastrointestinal bleeding

55 (6.2)

467 (10.1)

,.001
,.001

End-stage renal disease

Diabetes mellitus

.408
.003

.006

Cerebrovascular accident

114 (12.8)

400 (8.7)

Substance abuse

212 (23.9)

1289 (27.9)

.013

9 (1.0)

54 (1.2)

.687

Delirium or altered mental status

97 (10.9)

1276 (27.7)

,.001

Seizures

49 (5.5)

417 (9.0)

,.001

108 (12.2)

804 (17.4)

,.001

Myocardial infarction

65 (7.3)

337 (7.3)

Dialysis (any type)

60 (6.8)

490 (10.6)

,.001

Medical

34 (3.8)

2468 (53.5)

,.001

Surgical/trauma

18 (2.0)

852 (18.5)

,.001

Cardiac/cardiac surgery

61 (6.9)

769 (16.7)

,.001

Neurosciences

21 (2.4)

350 (7.6)

,.001

754 (84.9)

174 (3.8)

,.001

553 (62.3)

2729 (59.2)

33 (3.7)

177 (3.8)

184 (20.7)

488 (10.6)

,.001
,.001

HIV infection

Chronic obstructive pulmonary disease

.988

Intensive care unit type, No. (%)

Mixed
Intensive care admission source, No. (%)
Emergency department
Skilled nursing, long-term acute care
Scheduled procedure
Nonprocedure; clinic or direct admission

37 (4.2)

812 (17.6)

Other

81 (9.1)

407 (8.8)

.083
.863

.774

Intensive care admission diagnosis, No. (%)
Acute hypercapnic respiratory failure

25 (2.8)

233 (5.1)

.003

Acute hypoxemic respiratory failure

152 (17.1)

893 (19.4)

.123

30 (3.4)

124 (2.7)

.253

1 (0.1)

45 (1.0)

.004

Acute myocardial infarction
Acute renal failure or severe electrolyte abnormality
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Treatment exposures, No. (%)b

Table 1. Continued
Europe High-Risk Patients (n = 888)

Characteristic

United States High-Risk Patients (n = 4613)

P Value
,.001

Altered mental status

97 (10.9)

337 (7.3)

Cardiogenic shock

27 (3.0)

86 (1.9)

.028

Cerebrovascular accidentc

76 (8.6)

191 (4.1)

,.001

Hemorrhagic shock or severe hemorrhage

26 (2.9)

94 (2.0)

.103

6 (0.7)

17 (0.4)

.248

Other hypovolemic shock

475 (10.3)

,.001

94 (10.6)

337 (7.3)

,.001

Shock

15 (1.7)

41 (0.9)

.042

Frequent/refractory seizures

49 (5.5)

94 (2.0)

,.001

Traumac
Other

68 (7.7)

275 (6.0)

155 (17.5)

1371 (29.7)

.056
,.001

Abbreviations: H2, histamine blocker; HABP, hospital-acquired bacterial pneumonia; ICU, intensive care unit; IQR, interquartile range; NYHA, New York Heart Association; PPI, proton pump
inhibitor; VABP, ventilator-associated bacterial pneumonia.
a

Characteristics recorded at the time of high-risk population enrollment.

b

Characteristics recorded when pneumonia diagnosis was conﬁrmed or upon ICU discharge (for patients not developing HABP/VABP).

c

Items associated with higher odds of HABP/VABP development in the US cohort.

d

Diagnoses included in the active medical problem categories deﬁned in the Supplementary Data.

cerebrovascular accident and receipt of enteral nutrition were
identiﬁed as key patient characteristics and treatment exposures associated with increased odds of meeting the study
HABP/VABP end point (Supplementary Table 3). In contrast
to the US multivariable model, source of ICU admission, diabetes mellitus, and type of mechanical ventilation exposure were
not retained in the ﬁnal model. No collinearity that would compromise the stability of the model was identiﬁed. The multivariable model demonstrated discriminatory capacity, calibration
(c-statistic, 0.751 [0.708–0.794]), and no signiﬁcant lack of ﬁt
(χ2 = 7.66; P = .468). SOD/SDD exposure was subsequently
added to the multivariable logistic regression model. In the
model incorporating this new variable, SOD/SDD exposure
was associated with a lower risk of developing HABP/VABP
(adjusted odds ratio, 0.56 [0.34–0.93]; P = .024). The discriminatory capacity of the multivariable model incorporating SOD/

A,

SDD was similar (c-statistic, 0.756 [0.713–0.799]), but the model ﬁt and calibration were less satisfactory than the main model
(χ2 = 14.28; P = .075) (Supplementary Table 4).
Microbiologic culture results were reported in 148/150
(99%) high-risk patients meeting the study HABP/VABP deﬁnition. At least 1 bacterial pathogen was identiﬁed in 104/129
(81%) patients meeting the study criteria for VABP, a signiﬁcantly higher proportion than in the US cohort (235/357
[66%]; P = .002) (Supplementary Table 5). A higher proportion
of VABP patients in the European cohort had lower respiratory
tract culture results reported (Supplementary Table 6). At least
1 bacterial pathogen was identiﬁed in 12/19 (63%) patients
meeting the study criteria for HABP (Supplementary
Table 7). Klebsiella species were most commonly isolated
from high-risk patients meeting the VABP criteria in the
European cohort. In contrast, Staphylococcus aureus was

B,
Europe (n = 211)
P<.001

United States (n = 1464)

Europe (n = 211)

P<.001

United States (n = 1464)

P<.001

% treated patients

% treated patients

P<.001

P=.002

P=.002

Figure 3. Summary of study outcome (A) and patients lacking diagnostic criteria (B) for high-risk patients treated for possible HABP/VABP. Abbreviation: HABP/VABP,
hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia.
6 • OFID • Bergin et al
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174 (19.6)

Sepsis or septic shock

Planned postoperative ICU admission

most commonly isolated from patients meeting the study
HABP or VABP criteria in the US cohort.

DISCUSSION

Three important observations were derived from this large contemporary, prospectively enrolled cohort of critically ill patients. First, HABP/VABP remains a common complication
of critical illness. Application of simple clinical criteria effectively identiﬁed a cohort of patients at high risk; 17% of these
prospectively identiﬁed high-risk patients met standard case
deﬁnitions for HABP or VABP during their ICU course.
Second, the majority of prospectively identiﬁed high-risk patients meeting the standard HABP/VABP diagnostic criteria
are potentially eligible for enrollment in antibacterial clinical
trials: 83% of patients in Europe and 69% of those in the US

who met the study HABP/VABP deﬁnition also met the
FDA-recommended eligibility criteria for enrollment in an antibacterial trial. Third, a higher HABP/VABP incidence in the
European cohort, combined with lower rates of antibiotic prescription for patients not meeting the HABP/VABP diagnostic
criteria, may underlie reported discrepancies in HABP/VABP
antibacterial trial enrollment rates and feasibility between
Europe and the United States. These pivotal observations advance our understanding of the contemporary burden of nosocomial pneumonia, the prevalence of common trial exclusion
criteria in the HABP/VABP population, and differences in
European and US high-risk populations, which may inform future HABP/VABP registrational trial design and feasibility.
Low enrollment rates underlying the poor feasibility of
HABP/VABP antibacterial registrational trials are well documented and have not signiﬁcantly changed over the past 2
Pneumonia in Two High-risk ICU Populations • OFID • 7
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Figure 4. Comparison of HABP/VABP patients eligible for trial enrollment. Abbreviation: HABP/VABP, hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia.
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FDA-recommended registrational trial eligibility criteria, 36%
of those enrolled in Europe and 57% of those from the US
cohort had at least 1 additional exclusion criterion commonly
incorporated into eligibility criteria for HABP/VABP registrational trials conducted over the past 2 decades. These ﬁndings
advance our understanding of the impact of incorporating
additional exclusion criteria into HABP/VABP registrational
trial protocols, suggesting that design of pragmatic trials with
fewer sponsor-mandated exclusion criteria may signiﬁcantly
improve antibacterial trial feasibility.
Contemporary comparisons of high-risk patient characteristics, treatment exposures, HABP/VABP incidence, and prevalence of common HABP/VABP registrational trial exclusion
criteria are essential to understanding observed regional variation in clinical trial enrollment rates [7,17]. In this study, a
signiﬁcantly higher incidence of patients who met the HABP/
VABP study criteria was observed in the European high-risk
cohort: 17% vs 12% in the US cohort (P , .001). A higher
prevalence of established risk factors for HABP/VABP in the
European high-risk population (primary ICU admission
diagnoses of trauma or cerebrovascular accident, receipt of
enteral nutrition, receipt of systemic antibacterials within the
preceding 90 days) may partially account for this difference.
Whether other treatment exposures, speciﬁcally the threshold
to administer empiric antibacterials for suspected nosocomial
pneumonia, inﬂuence the observed differences in HABP/
VABP incidence is unknown. Despite a lower incidence of
HABP/VABP, high-risk patients in the US cohort were treated
with antibiotics for possible nosocomial pneumonia signiﬁcantly more than those patients in the European cohort: 32%
vs 24% of high-risk patients (P , .001). In the US cohort,
63% of high-risk patients receiving antibacterials for possible
nosocomial pneumonia did not meet the study criteria for
HABP/VABP; a signiﬁcantly lower proportion was observed
in the European cohort (29%; P , .001). This diagnostic outcome discrepancy was driven primarily by the lack of radiographic criteria in treated high-risk US patients (40% vs 18%
in the European cohort; P , .001). It is unknown if a lower
threshold to treat ventilator-associated tracheobronchitis in
the US cohort, which has been associated with a lower risk of
progression to VABP, inﬂuenced the discrepancy in observed
VABP rates [22]. Although the design of this study precludes
direct evaluation, these observations raise concern for antibiotic
overprescription for syndromes that do not fulﬁll the standard
HABP/VABP criteria, which may increase the risk for adverse
events and underlie observed differences in the proportion of
HABP/VABP patients meeting FDA-recommended eligibility
criteria for registrational trial enrollment.
This study has important limitations. First, because only ICU
patients meeting predeﬁned high-risk criteria (a requirement
for high levels of respiratory support) were enrolled, nonventilated HABP, which comprises the largest proportion of
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decades [7, 13, 15]. A decreasing incidence of VABP has been
proposed as a contributor to low enrollment rates. The CTTI
HABP/VABP study team recently published ﬁndings from a
large cohort of critically ill patients requiring signiﬁcant respiratory support in the United States in which 32% of high-risk
patients received antibacterial treatment for possible HABP/
VABP and 12% of the high-risk population ultimately met
the clinical criteria for HABP/VABP during their ICU course
[16]. In this cohort of high-risk patients enrolled from the
ICUs of 7 European hospitals, a signiﬁcantly higher incidence
of HABP/VABP was observed: 17% of the high-risk population
met the study HABP/VABP deﬁnition. This observation stands
in contrast to surveillance data suggesting declining rates of
nosocomial pneumonia, providing additional evidence that
HABP/VABP remains a common complication of critical illness, at least among patients already requiring signiﬁcant respiratory support [1, 20]. This study was not designed to estimate
the incidence of HABP outside the ICU setting, but the ﬁndings
suggest that declining rates of HABP/VABP in critically ill patients are not a signiﬁcant driver of low enrollment rates in
HABP/VABP registrational trials.
A high prevalence of prior antibiotic exposure and medical
comorbidities resulting in clinical trial ineligibility has also
been implicated as a driver of low enrollment in HABP/
VABP registrational trials. Prior effective antibacterial therapy
can signiﬁcantly confound the evaluation of study drug efﬁcacy
in pneumonia noninferiority trials [21]. US FDA guidance for
industry recommends excluding patients exposed to .24
hours of potentially effective antibacterial therapy from enrollment in HABP/VABP registrational trials [18]. Because exposure to broad-spectrum antibacterials is common in critically
ill patients, this exclusion criterion has been implicated as a signiﬁcant determinant of clinical trial enrollment. Our ﬁndings
suggest that exposure to prior effective antibiotic therapy
would result in HABP/VABP registrational trial ineligibility
in a minority of HABP/VABP patients. Among high-risk patients meeting the study HABP/VABP deﬁnition, 17% in the
European cohort and 31% in the US cohort had been exposed
to .24 hours of potentially effective antibiotic therapy at the
time of HABP/VABP diagnosis. This observation may overestimate the number of patients excluded because of prior effective antibacterial therapy, as we were unable to estimate the
proportion of HABP/VABP patients with progressive pneumonia despite prolonged exposure to antibacterials—for whom
registrational trial enrollment would be appropriate because
the prior antibacterial regimen failed. Although not required
by regulatory agencies, additional exclusion criteria are commonly incorporated into HABP/VABP antibacterial trial
protocols. Our observations suggest that these additional
exclusion criteria may reduce registrational trial enrollment
rates more than excessive prior antibacterial therapy
exposure (Figure 4). Among enrolled patients meeting

CONCLUSIONS

In conclusion, applying simple clinical criteria effectively identiﬁed a cohort of critically ill patients at high risk for developing
HABP/VABP in Europe and the United States. Most prospectively identiﬁed high-risk patients developing nosocomial
pneumonia met the recommended eligibility criteria for enrollment in HABP/VABP registrational drug trials. Differences in
patient characteristics and treatment practices may contribute
to observed differences in registrational trial enrollment. An
improved understanding of these differences and applying simple clinical criteria to prospectively identify patients at high risk
for HABP/VABP may improve registrational trial feasibility

and foster development of new antibacterial treatments for
nosocomial pneumonia.
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nosocomial pneumonia, is underrepresented [23]. The ﬁndings
of this study may not apply to patients not meeting the study
high-risk deﬁnition. Second, the observations derived from
these cohorts enrolled in the United States and Western
Europe may not be generalizable to high-risk patients in
Eastern Europe or other parts of the world. The primary reason
we enrolled patients in both the European Union and the
United States was to evaluate drivers of documented regional
variability in HABP/VABP incidence and HABP/VABP registrational trial enrollment [1, 13]. However, data from HABP/
VABP registrational trials submitted to the US FDA since
2015 suggest that enrollment rates at Western European and
North American sites are relatively similar and among the lowest observed worldwide [7]. Because we did not enroll patients
from regions of the world associated with the highest HABP/
VABP trial enrollment rates, we cannot evaluate key drivers
of these discordant enrollment rates. While this study may
not be generalizable to regions with historically higher registrational trial enrollment rates (Eastern Europe, Asia, South
America), the ﬁndings signiﬁcantly enhance our understanding
of HABP/VABP trends and potentially eligible HABP/VABP
patient populations in regions where these critical registrational trials are less feasible. Third, because this was an observational cohort study, other unmeasured differences between the
enrolled European and US cohorts may have inﬂuenced the observed differences in treatment exposures, HABP/VABP incidence, and estimated rates of registrational trial eligibility.
Fourth, it is possible that changes in patient characteristics or
treatment practices since enrollment completion in 2017 diminish the applicability of these ﬁndings to the design of new
HABP/VABP antibacterial drug trials. Fifth, the duration of
study enrollment precluded an analysis of seasonal trends in
HABP/VABP incidence and treatment exposures that may be
impacted by prevalence of viral pneumonia [24]. Finally,
whether enrollment of the European cohort in a different season and beginning 9 months after completion of US enrollment contributed to observed differences in treatment
patterns or HABP/VABP incidence is unknown.
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